Key Highlights:
- AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation has approved Durvalumab in combination with FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin and docetaxel) as a perioperative immunotherapy option for adults with resectable gastric or gastroesophageal junction adenocarcinoma.
- The approval is based on results from the Phase III MATTERHORN study, allowing durvalumab to be used alongside FLOT chemotherapy in neoadjuvant and adjuvant settings, followed by maintenance treatment with durvalumab alone.
- In the MATTERHORN trial, the durvalumab plus FLOT regimen demonstrated a 28% reduction in the risk of event-free survival events or death and a 21% relative reduction in mortality compared with chemotherapy alone, supporting the earlier integration of immunotherapy in treating Gastric Cancer and Gastroesophageal Junction Cancer.
Implications:
Durvalumab storms earlier gastric cancer treatment, snatching share from chemo-only protocols as oncologists embrace immunotherapy combo superiority.
High-recurrence gastric cases become AstraZeneca’s stronghold, pressuring Roche/MSD while hospitals scramble for perioperative regimen adoption.
Approval accelerates solid tumor immuno-oncology shift, handing AstraZeneca killer edge in India’s exploding GI cancer pipeline.
Source: Expresspharma | Image: AstraZeneca
No Comment! Be the first one.